Asciminib hydrochloride is described as a STAMP inhibitor, specifically targeting the ABL myristoyl pocket, Asciminib hydrochloride, marketed as Scemblix, are applied in research in Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) by binding to the allosteric site of wild-type ABL N-terminus, which is myristoylated, whereas the ABL fusion protein lacks this domain, enabling selective modulation of oncogenic signaling pathways and serving as a targeted therapeutic tool in hematologic cancer research.
Molekulargewicht:
486.3
Reinheit:
99.91%
CAS Nummer:
[2119669-71-3]
Formel:
C20H19Cl2F2N5O3
Target-Kategorie:
Bcr-Abl
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
